Literature DB >> 20215580

A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion.

Soonkyu Chung1, Abraham K Gebre, Jeongmin Seo, Gregory S Shelness, John S Parks.   

Abstract

In Tangier disease, absence of ATP binding cassette transporter A1 (ABCA1) results in reduced plasma HDL and elevated triglyceride (TG) levels. We hypothesized that hepatocyte ABCA1 regulates VLDL TG secretion through nascent HDL production. Silencing of ABCA1 expression in oleate-stimulated rat hepatoma cells resulted in: 1) decreased large nascent HDL (>10 nm diameter) and increased small nascent HDL (<10 nm) formation, 2) increased large buoyant VLDL1 particle secretion, and 3) decreased phosphatidylinositol-3 (PI3) kinase activation. Nascent HDL-containing conditioned medium from rat hepatoma cells or HEK293 cells transfected with ABCA1 was effective in increasing PI3 kinase activation and reducing VLDL TG secretion in ABCA1-silenced hepatoma cells. Addition of isolated large nascent HDL particles to ABCA1-silenced hepatoma cells inhibited VLDL TG secretion to a greater extent than small nascent HDL. Similarly, addition of recombinant HDL, but not human plasma HDL, was effective in attenuating TG secretion and increasing PI3 kinase activation in ABCA1-silenced cells. Collectively, these data suggest that large nascent HDL particles, assembled by hepatic ABCA1, generate a PI3 kinase-mediated autocrine signal that attenuates VLDL maturation and TG secretion. This pathway may explain the elevated plasma TG concentration that occurs in most Tangier subjects and may also account, in part, for the inverse relationship between plasma HDL and TG concentrations in individuals with compromised ABCA1 function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215580      PMCID: PMC2842152          DOI: 10.1194/jlr.M900083

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  56 in total

1.  Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice.

Authors:  E Orsó; C Broccardo; W E Kaminski; A Böttcher; G Liebisch; W Drobnik; A Götz; O Chambenoit; W Diederich; T Langmann; T Spruss; M F Luciani; G Rothe; K J Lackner; G Chimini; G Schmitz
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

3.  Conformational and thermodynamic properties of apo A-1 of human plasma high density lipoproteins.

Authors:  A R Tall; G G Shipley; D M Small
Journal:  J Biol Chem       Date:  1976-06-25       Impact factor: 5.157

4.  Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes.

Authors:  C E Sparks; J D Sparks; M Bolognino; A Salhanick; P S Strumph; J M Amatruda
Journal:  Metabolism       Date:  1986-12       Impact factor: 8.694

5.  Effect of fish oil diet on hepatic lipid metabolism in nonhuman primates: lowering of secretion of hepatic triglyceride but not apoB.

Authors:  J S Parks; F L Johnson; M D Wilson; L L Rudel
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

6.  Prebeta high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice.

Authors:  Ji-Young Lee; Lorraine Lanningham-Foster; Elena Y Boudyguina; Thomas L Smith; Ellen R Young; Perry L Colvin; Michael J Thomas; John S Parks
Journal:  J Lipid Res       Date:  2004-01-16       Impact factor: 5.922

7.  Identification of the lipoprotein initiating domain of apolipoprotein B.

Authors:  Gregory S Shelness; Li Hou; Aubrey S Ledford; John S Parks; Richard B Weinberg
Journal:  J Biol Chem       Date:  2003-08-26       Impact factor: 5.157

8.  Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBalpha.

Authors:  Crystal S Au; Amy Wagner; Taryne Chong; Wei Qiu; Janet D Sparks; Khosrow Adeli
Journal:  Metabolism       Date:  2004-02       Impact factor: 8.694

9.  Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients.

Authors:  J D Morrisett; G Abdel-Fattah; B D Kahan
Journal:  Transplant Proc       Date:  2003-05       Impact factor: 1.066

10.  ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes.

Authors:  Daisy Sahoo; Timothy C Trischuk; Teddy Chan; Victor A B Drover; Samuel Ho; Giovanna Chimini; Luis B Agellon; Ricky Agnihotri; Gordon A Francis; Richard Lehner
Journal:  J Lipid Res       Date:  2004-03-01       Impact factor: 5.922

View more
  23 in total

1.  Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo.

Authors:  Soonkyu Chung; Janet K Sawyer; Abraham K Gebre; Nobuyo Maeda; John S Parks
Journal:  Circulation       Date:  2011-09-19       Impact factor: 29.690

Review 2.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

3.  Hepatic ABCA1 deficiency is associated with delayed apolipoprotein B secretory trafficking and augmented VLDL triglyceride secretion.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-07-08       Impact factor: 4.698

4.  Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor.

Authors:  Alexander C Bashore; Mingxia Liu; Chia-Chi C Key; Elena Boudyguina; Xianfeng Wang; Caitlin M Carroll; Janet K Sawyer; Adam E Mullick; Richard G Lee; Shannon L Macauley; John S Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06-06       Impact factor: 8.311

5.  Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism.

Authors:  Soonkyu Chung; Jenelle M Timmins; Myngan Duong; Chiara Degirolamo; Shunxing Rong; Janet K Sawyer; Roshni R Singaraja; Michael R Hayden; Nobuyo Maeda; Lawrence L Rudel; Gregory S Shelness; John S Parks
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

6.  Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion.

Authors:  Anna M Blade; Melissa A Fabritius; Li Hou; Richard B Weinberg; Gregory S Shelness
Journal:  J Lipid Res       Date:  2010-11-26       Impact factor: 5.922

7.  "Who's on first": determining the roster for the key players in the reverse cholesterol transport pathway.

Authors:  A T Remaley
Journal:  Atherosclerosis       Date:  2011-07-07       Impact factor: 5.162

8.  BMP7 drives human adipogenic stem cells into metabolically active beige adipocytes.

Authors:  Meshail Okla; Jung-Heun Ha; Ryan E Temel; Soonkyu Chung
Journal:  Lipids       Date:  2014-12-23       Impact factor: 1.880

9.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

10.  MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.

Authors:  Takayoshi Shirasaki; Masao Honda; Tetsuro Shimakami; Rika Horii; Taro Yamashita; Yoshio Sakai; Akito Sakai; Hikari Okada; Risa Watanabe; Seishi Murakami; MinKyung Yi; Stanley M Lemon; Shuichi Kaneko
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.